The overall ORR was 62.6% (95% CI 53.8–71.0), which was slightly higher in studies targeting BCMA in myeloma cells (64.0%, 95% CI 51.5–75.7) as compared to BsAbs targeting non-BCMA receptors (62.0%, 95% CI 53.6–70.1). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.